Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Rising Leverage ⢠Margin Pressure TGTX has strong liquidity and improving quarterly cash flow, but weakening margins, rising leverage, dilution, and richer valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly rally ⢠Overbought momentum ⢠Key support test Support Level: $54.30â$55.00 Resistance Level: $56.90 TGTX remains bullish over the last month but is extended near $56.90 resistance, so watch $54.30â$55.00 support for consolidation risk.
Sentiment & News
Key News Insights: ⢠Raised Revenue Outlook ⢠Pipeline Catalysts ⢠Buyout Speculation TG Therapeutics' raised Briumvi outlook, pipeline catalysts, and buyout speculation support momentum, though consensus remains Hold.
AI Summary
TGTX has shifted into a BRIUMVI-driven commercial growth story, but at a premium valuation and higher leverage, investors should require sustained sales outperformance and clear operating-margin/free-cash-flow expansion before adding exposure, as any MS franchise slowdown would have outsized downside.
Description
TG Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes therapies for Bâcell malignancies and certain autoimmune disorders. Its pipeline combines monoclonal antibodies and oral small-molecule inhibitorsâtargeting Bâcell receptors and immune checkpointsâalongside early-stage programs in epigenetics and immune signaling, supported by multiple licensing and collaboration agreements with international partners. The company was incorporated in 1993 and is headquartered in New York, NY.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 6 | May 13 | TGTX | TG Therapeutics, Inc. | Q1 2026 revenue around $205M, full-year guidance raised to about $925M total global revenue, BRIUMVI execution remains strong, and technical momentum is favorable with about 16% 21-day gain and 17% in the last 5 sessions. | Closed | +1.6% |